1. Alvarez-Tutor E, Forga-LLenas L, Rodriguez-Erdozain R, Goñi-Iriarte MJ, Menendez-Torre E, Alvarez-Tutor J. Persistent increase of PRL after oral contraceptive treatment. Arch Gynecol Obstet. 13 de diciembre de 1999; 263(1-2):45-50
2. Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C (2014) Hyperprolactinémies induites par les antipsychotiques : physiopathologie, clinique et surveillance. L’Encéphale. Febrero de 40(1):86–94
3. Byerly M, Suppes T, Tran QV, Baker RA (2007) Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. Diciembre de 27(6):639–661
4. Cano AM, Mendiguchía LJ, Coronado MR, Lozano AG, del Rey-Mejías ÁL, Merino MF, Pinedo MM, Araujo-Castro M. Causes of hyperprolactinaemia in the primary care setting: how to optimize hyperprolactinaemia management | Elsevier Enhanced Reader [Internet]. [citado 1 de junio de 2022]. Disponible en: https://reader.elsevier.com/reader/sd/pii/S2530016422001136?token=C164C4B3B7801502B4CDB27EC485D266A997B1C647495A70F4AAEE8DB82D3F45100C9DA4B00824A75D3A9BE3A83BD8C1&originRegion=eu-west-1&originCreation=20220601054604
5. Capozzi A, Scambia G, Pontecorvi A, Lello S (2015) Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol. 3 de julio de 31(7):506–510